Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Neelima Vidula, M.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Vidula N, Greenberg S, Petrillo L, Hwang J, Melisko M, Goga A, Moasser M, Magbanua M, Park JW, Rugo HS. Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. NPJ Breast Cancer. 2021 Sep 06; 7(1):113. PMID: 34489453.
    Citations:    
  2. Rolfo C, Drilon A, Hong D, McCoach C, Dowlati A, Lin JJ, Russo A, Schram AM, Liu SV, Nieva JJ, Nguyen T, Eshaghian S, Morse M, Gettinger S, Mobayed M, Goldberg S, Araujo-Mino E, Vidula N, Bardia A, Subramanian J, Sashital D, Stinchcombe T, Kiedrowski L, Price K, Gandara DR. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. Br J Cancer. 2021 Sep 03. PMID: 34480094.
    Citations:    Fields:    
  3. LoRusso P, Hamilton E, Ma C, Vidula N, Bagley RG, Troy S, Annett M, Yu Z, Conlan MG, Weise A. A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer. Clin Breast Cancer. 2021 Aug 20. PMID: 34565686.
    Citations:    Fields:    
  4. Nagayama A, Vidula N, Bardia A. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates. Oncology (Williston Park). 2021 05 13; 35(5):249-254. PMID: 33983696.
    Citations:    Fields:    
  5. Vidula N, Yau C, Rugo HS. Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer. Breast Cancer Res Treat. 2021 Jun; 187(2):387-395. PMID: 33913053.
    Citations:    Fields:    Translation:HumansCells
  6. Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, Juric D, Kuter I, Sanidas I, Moy B, Mulvey T, Vidula N, Dyson NJ, Ellisen LW, Isakoff S, Wagle N, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Bardia A. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. J Natl Compr Canc Netw. 2021 Mar 24; 1-8. PMID: 33761455.
    Citations:    Fields:    
  7. Vidula N, Niemierko A, Malvarosa G, Yuen M, Lennerz J, Iafrate AJ, Wander SA, Spring L, Juric D, Isakoff S, Younger J, Moy B, Ellisen LW, Bardia A. Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2021 Jun 15; 27(12):3404-3413. PMID: 33504549.
    Citations:    Fields:    
  8. Vidula N, Ellisen LW, Bardia A. Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer. Oncotarget. 2021 Jan 19; 12(2):63-65. PMID: 33520111.
    Citations:    Fields:    
  9. Vidula N, Ellisen LW, Bardia A. Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative. J Natl Compr Canc Netw. 2020 10 15; 1-9. PMID: 33075745.
    Citations: 1     Fields:    
  10. Vidula N, Dubash T, Lawrence MS, Simoneau A, Niemierko A, Blouch E, Nagy B, Roh W, Chirn B, Reeves BA, Malvarosa G, Lennerz J, Isakoff SJ, Juric D, Micalizzi D, Wander S, Spring L, Moy B, Shannon K, Younger J, Lanman R, Toner M, Iafrate AJ, Getz G, Zou L, Ellisen LW, Maheswaran S, Haber DA, Bardia A. Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2020 09 15; 26(18):4852-4862. PMID: 32571788.
    Citations: 2     Fields:    
  11. Nagayama A, Vidula N, Ellisen L, Bardia A. Novel antibody-drug conjugates for triple negative breast cancer. Ther Adv Med Oncol. 2020; 12:1758835920915980. PMID: 32426047.
    Citations: 8     
  12. Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan AC, Brufsky AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 06 01; 26(11):2546-2555. PMID: 32034076.
    Citations: 8     Fields:    Translation:HumansCells
  13. Vidula N, Yau C, Wolf D, Rugo HS. Androgen receptor gene expression in primary breast cancer. NPJ Breast Cancer. 2019; 5:47. PMID: 31840050.
    Citations: 4     
  14. Vidula N, Yau C, Wolf D, Rugo HS. Androgen receptor gene expression in primary breast cancer. NPJ Breast Cancer. 2019 Dec 10; 5(1):47. PMID: 33293509.
    Citations:    
  15. Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A. FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. Clin Cancer Res. 2019 11 01; 25(21):6443-6451. PMID: 31371343.
    Citations: 13     Fields:    Translation:Humans
  16. Medford AJ, Dubash TD, Juric D, Spring L, Niemierko A, Vidula N, Peppercorn J, Isakoff S, Reeves BA, LiCausi JA, Wesley B, Malvarosa G, Yuen M, Wittner BS, Lawrence MS, Iafrate AJ, Ellisen L, Moy B, Toner M, Maheswaran S, Haber DA, Bardia A. Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. NPJ Precis Oncol. 2019; 3:18. PMID: 31341951.
    Citations: 8     
  17. Vidula N, Rugo HS. Emerging data on improving response to hormone therapy: the role of novel targeted agents. Expert Rev Anticancer Ther. 2018 01; 18(1):3-18. PMID: 29192520.
    Citations: 2     Fields:    Translation:HumansCells
  18. Vidula N, Bardia A. Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology. Oncotarget. 2017 Dec 05; 8(63):106167-106168. PMID: 29290935.
    Citations: 7     Fields:    
  19. Vidula N, Yau C, Li J, Esserman LJ, Rugo HS. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2017 Aug; 165(1):129-138. PMID: 28577080.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  20. Rugo HS, Vidula N, Ma C. Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. Am Soc Clin Oncol Educ Book. 2016; 35:e40-54. PMID: 27249746.
    Citations: 18     Fields:    Translation:Humans
  21. Vidula N, Villa M, Helenowski IB, Merchant M, Jovanovic BD, Meagher R, Mehta J, Singhal S, Winter JN, Frankfurt O, Altman JK, Williams SF, Gordon LI. Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):e157-62. PMID: 26482109.
    Citations: 2     Fields:    Translation:HumansCells
  22. Vidula N, Rugo HS. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data. Clin Breast Cancer. 2016 Feb; 16(1):8-17. PMID: 26303211.
    Citations: 26     Fields:    Translation:Humans
  23. Vidula N, Rugo HS. Translating the molecular message of triple-negative breast cancer into targeted therapy. Clin Cancer Res. 2015 Apr 01; 21(7):1511-3. PMID: 25351747.
    Citations: 1     Fields:    Translation:HumansCells
  24. Vidula N, Qamar N, Kurahashi C, Chadha V, Evans D, Peters A. Encephalopathy and strokes secondary to drug reaction with eosinophilia and systemic symptoms: a case report. J Allergy Clin Immunol Pract. 2014 Mar-Apr; 2(2):222-4. PMID: 24607054.
    Citations: 1     Fields:    Translation:Humans
  25. Vidula N, Johnson M, Didwania A. Therapeutic case conference from Northwestern: an elderly gentleman with an unsteady gait. Am J Ther. 2012 May; 19(3):199-203. PMID: 22314212.
    Citations:    Fields:    Translation:Humans
  26. Moinnes JJ, Vidula N, Halim N, Othman SF. Ultrasound accelerated bone tissue engineering monitored with magnetic resonance microscopy. Conf Proc IEEE Eng Med Biol Soc. 2006; 2006:484-8. PMID: 17946836.
    Citations: 1     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Vidula's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (91)
Explore
_
Co-Authors (28)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.